DUBLIN, Apr. 10, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Cardiovascular Disorders Drug Development Pipeline Review, 2017" report to their offering.
The report provides comprehensive information on the pipeline development landscape for Hypertension, Dyslipidemia, Venous thromboembolism and Heart failure, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.
There are over 1,200 pipeline products within the CVD therapy area. Over 50% of these products are small molecules however there is also diversification with regards to molecule types within the pipeline. In addition, the molecular targets in the pipeline are considerably diverse with a high frequency of products acting on targets related to lipid metabolism and those which act on elements of the coagulation cascade.
Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as PCSK9 inhibitors and direct factor Xa inhibitors.
Key Topics Covered:
1. Research Report Guidance
2. Executive Summary
4. Cardiovascular Disorders Report Coverage
5. Therapeutics Development
6. Therapeutics under Development by Companies
7. Therapeutics under Investigation by Universities/Institutes
8. Pipeline Products Glance
9. Products under Development by Companies
10. Products under Investigation by Universities/Institutes
11. Companies Involved in Therapeutics Development
12. Therapeutics Assessment
13. Discontinued Products
14. Product Development Milestones
For more information about this report visit http://www.researchandmarkets.com/research/834p96/cardiovascular
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cardiovascular-disorders-drug-development-pipeline-review-2017-1200-pipeline-products-within-the-cvd-therapy-area---research-and-markets-300437192.html
SOURCE Research and Markets